Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Kanishk Kumar on 2034 Forecasts for aHUS Associated Thrombotic Microangiopathy
Kanishk Kumar/LinkedIn
Dec 28, 2025, 17:18

Kanishk Kumar on 2034 Forecasts for aHUS Associated Thrombotic Microangiopathy

Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, shared on LinkedIn:

”Atypical Hemolytic Uremic Syndrome Market 2034: Targeting Complement-Mediated Thrombotic Microangiopathy

Atypical Hemolytic Uremic Syndrome (aHUS), a rare thrombotic microangiopathy caused by uncontrolled complement activation, is advancing with novel C5 inhibitors and factor B blockers in 2034.

Delve Insight‘s report covers epidemiology in the 7MM (US, EU4, UK, Japan), market dynamics, and forecasts, projecting significant CAGR from 2020-2034, with ~4,800 diagnosed cases in 7MM in 2023, ~3,500 in US, and adolescents/adults representing ~80% of cases.

Key Developments in aHUS Market:

December 11, 2025: Novartis launched a Phase 3 study of iptacopan in treatment-naive aHUS patients.

December 8, 2025: Alexion Pharmaceuticals, Inc. disclosed a Phase 3b study of eculizumab in Chinese aHUS patients.

Leading Atypical Hemolytic Uremic Syndrome Companies include Novartis, Hoffmann-La Roche, Chugai Pharmaceutical Co., Ltd., Alexion Pharmaceuticals, Inc. , and others.

Promising therapies include Eculizumab, Crovalimab, Iptacopan, NM8074, Ravulizumab, ULTOMIRIS, SOLIRIS, and others.

Delve Insight’s comprehensive report on Atypical Hemolytic Uremic Syndrome Market Insights, Epidemiology and Market Forecast – 2034”

Find the full report here.

Read the full post.

Kanishk Kumar on 2034 Forecasts for aHUS Associated Thrombotic Microangiopathy

Stay updated with Hemostasis Today.

aHUS Alexion Pharmaceuticals CAGR Chugai Pharmaceutical Co. Crovalimab eculizumab Health Hematology Hemostasis Hemostasis Today Hoffmann-La Roche Iptacopan Kanishk Kumar Medicine Novartis Ravulizumab SOLIRIS thrombosis thrombotic microangiopathy ULTOMIRIS
NewsFeed